{"id":"askp1240","safety":{"commonSideEffects":[{"rate":"40-60%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL3990028","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PI3Kδ, ASKP1240 is thought to modulate B-cell receptor signaling and potentially treat various B-cell malignancies.","oneSentence":"ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:22.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory follicular lymphoma"},{"name":"Relapsed or refractory marginal zone lymphoma"}]},"trialDetails":[{"nctId":"NCT01780844","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-03-05","conditions":"Kidney Transplantation","enrollment":149},{"nctId":"NCT01585233","phase":"PHASE2","title":"A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-04-30","conditions":"Psoriasis","enrollment":60},{"nctId":"NCT01279538","phase":"PHASE1","title":"A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-11-17","conditions":"Kidney Transplantation","enrollment":50},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT01565681","phase":"PHASE1","title":"Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2009-01","conditions":"Pharmacokinetics of ASKP1240, Healthy Volunteers","enrollment":109},{"nctId":"NCT01582399","phase":"PHASE1","title":"Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-02","conditions":"Pharmacokinetics of ASKP1240, Pharmacodynamics of ASKP1240, Healthy Volunteers","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ASKP1240","genericName":"ASKP1240","companyName":"Astellas Pharma Global Development, Inc.","companyId":"astellas-pharma-global-development-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory marginal zone lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}